Here are five observations:
1. This is the first trial in which a bone cell therapy product is placed percutaneously directly into the failed fusion area without an open procedure.
2. The product, called ALLOB, is designed to promote the fusion process though stimulation of bone formation.
3. The trial is a proof-of-concept Phase IIA, designed to test the safety of the ALLOB implantation in rescue spinal fusion over 12 months.
4. Sixteen patients with failed lumbar spinal fusions at 15 months or more after surgery will be treated with a single implantation.
5. Fluoroscopy helps with the visualization of the exact location of implant placement. CT-scans will evaluate the efficacy.
More articles on devices:
Global spinal implants and devices market to hit $15.7B by 2020: 5 things to know
Medacta achieves milestones in 2015: 5 key notes
Zimmer Biomet, Lima strike a deal for Japanese market rights: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
